Ethambutol
Ethambutol is a pharmaceutical drug with 43 clinical trials. Currently 9 active trials ongoing. Historical success rate of 87.5%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
19
Mid Stage
17
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.5%
21 of 24 finished
12.5%
3 ended early
9
trials recruiting
43
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Shortened Regimen for Drug-susceptible TB in Children
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
Clinical Trials (43)
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Shortened Regimen for Drug-susceptible TB in Children
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
Short-term Bactericidal Effect of Contezolid in MAC-PD
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
Hypertonic Saline for MAC
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 43